Refine by
Pancreatic Cancer Articles & Analysis
67 news found
The controversial subject of fighting cancer is no longer limited to chemotherapy and radiation, and vaccines, once a word tied almost exclusively to infections, are now headline players in oncology. As reported by UCLA Health, a novel cancer vaccine could trigger robust immune responses in patients with pancreatic and colorectal ...
Alfa Cytology, a premier contract research organization, recently launched its full-scale pancreatic cancer research services with robust platforms, powerful analytics, and cross-platform collaborations. Pancreatic cancer (PC) is a severe disease that is difficult to diagnose in the early stages due to its complex and ...
Cartherics is using its induced pluripotent stem (iPS) cell platform to develop NK cell, T-cell, and macrophage cell therapies with potential indications for solid tumour types including ovarian, gastric, prostate, pancreatic, liver, and kidney cancers. He also discusses several of the company’s near-term pipeline products and other areas of possible ...
Its first potential indication is pancreatic cancer, a particularly lethal disease that affects more than 53,000 Americans annually, where excruciating symptoms arise from the primary mass invading nearby vital organs. ...
Inhibiting CDK7 is a promising therapeutic strategy in cancer as CDK7 regulates the transcription of cancer-causing genes, promotes uncontrolled cell cycle progression and resistance to anti-hormone therapy. ...
Through this collaboration, xCures will help eligible pancreatic cancer patients access a Phase III clinical study entitled, Targeted Intra-arterial Gemcitabine vs. ...
ByxCures
“We are dedicated to helping people living with hard-to-treat cancers through our research and development of innovative treatments. ...
LOS ANGELES, CA – October 6, 2022 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the National Cancer Institute (NCI) and Rutgers University sites are open to recruit patients for the treatment of Kita-Kyushu lung cancer antigen 1 ...
Those incentives include tax credit on expenditures incurred in clinical studies, a waiver of the New Drug Application (NDA) fee, and 7-year market exclusivity in the U.S. regardless of the patent status of the designated drug. Pancreatic cancer is a highly malignant type of gastrointestinal cancer. According to the statistics by the World ...
“Vincere Cancer Center is committed to providing the best and latest cancer care. ...
Jubilant Therapeutics Inc. is developing a novel small molecule PAD4 inhibitor that directly targets this mechanism. The findings appear in Cancer Research, a journal of the American Association for Cancer Research. “Development of metastases remains a leading cause of death from cancer. Tumor-associated neutrophils have long been ...
Peptide drug conjugate (PDC) is emerging as a novel type of conjugate drug, showing advantageous features over antibody-drug conjugates (ADCs). As a dedicated peptide manufacturer, Creative Peptides provides a one-stop solution for all peptide drug bioconjugation needs to help pharmaceutical clients bring more PDCs to the market. Structurally, PDC mainly contains three elements—cytotoxin, ...
xCures, Inc. is proud to partner with Vault Health, a decentralized research and workforce screening company, to facilitate the enrollment of pancreatic cancer patients in Faeth Therapeutics’ NEAAR-001 research study. ...
ByxCures
Interpace also announced today new clinical validation data for our thyroid cancer test platform (ThyGeNEXT® + ThyraMIR®) was published online within THYROID®, the leading peer-reviewed journal for original research on thyroid cancer. ...
SEngine utilizes breakthrough science from cancer genomics, robotics, and proprietary algorithms. SEngine's CLIA certified PARIS® Test generates actionable drug sensitivity reports for patients and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer. ...
Congratulations to investigators at Hannover School of Medicine and Heidelberg University Hospital for receiving the 2022 SNMMI Image of the Year Award and JNM Editors’ Choice Award for Overall Best Article in 2021, respectively. Both use FAPI as the primary indicator and further underscore its potential impact as a novel radiopharmaceutical. Each year, SNMMI chooses an image that best ...
BySOFIE
About xCures xCures Inc. operates an AI-assisted platform that connects cancer patients and physicians with optimal investigational or approved therapies. ...
ByxCures
(Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 ...
Additionally, Galera’s Phase 2 GRECO-2 study of rucosopasem (GC4711) in combination with stereotactic body radiation therapy in pancreatic cancer will be presented at the ASCO Annual Meeting in a Trials in Progress poster session on Saturday, June 4, 2022, from 8:00 a.m. ...
In patients with head and neck cancer, radiotherapy is a mainstay of treatment. Approximately 70 percent of patients receiving radiotherapy for head and neck cancer develop SOM, defined by the inability to eat solid food or drink liquids. ...